India’s Semaglutide Patent Expiry to Slash Prices, Expand Obesity Treatment Access

The patent for semaglutide in India expired on March 20, 2026, marking a pivotal shift in the pharmaceutical sector and obesity treatment strategies. This development will enable over 50 branded generic versions of the drug to enter the market within months, reducing costs by approximately 50% and expanding access to weight-loss therapies. Branded versions such as Wegovy and Ozempic currently cost around Rs 10,000–16,000 per month and Rs 8,800–11,000 per month, respectively, according to the BBC.

Wegovy recently saw a 37% price reduction, aligning with broader industry efforts to improve affordability. Investment bank Jefferies has identified this as a potential opportunity for India, forecasting the semaglutide market could eventually reach $1 billion domestically with appropriate pricing and adoption. India’s pharmaceutical industry has a history of rapid response to patent expiries, exemplified by the diabetes drug sitagliptin, which saw 30 branded versions appear within a month and nearly 100 within a year after its patent expired in 2022. Major firms including Sun Pharma, Zydus Lifesciences, Dr. Reddy’s Laboratories, Natco Pharma, and Cipla are preparing to launch generic semaglutide, with prefilled pens and marketing partnerships facilitating swift distribution.

Analysts anticipate the anti-obesity market could grow ten-fold due to intensified competition, though this projection is based on industry trends rather than explicit data. This transition from premium innovator dominance to a generics-led market positions India as a global leader in affordable weight-loss solutions, potentially influencing pricing for Novo Nordisk’s branded products internationally.

“The patent for semaglutide in India expired on March 20, 2026, marking a pivotal shift in the pharmaceutical sector and obesity treatment strategies.”

Semaglutide, a GLP-1 receptor agonist, has become a critical tool in addressing obesity and diabetes in India. Initially developed for type 2 diabetes, the drug has gained recognition for its efficacy in weight loss, offering results that surpass many previous treatments. Its mechanism involves mimicking the hormone glucagon-like peptide-1 (GLP-1), which regulates appetite and blood sugar by increasing insulin release and slowing gastric emptying. This dual function makes it highly effective for patients with metabolic disorders. The availability of affordable generics will expand access to this therapy, particularly for India’s 77 million individuals with type 2 diabetes and its large population of overweight adults.

The oral formulation, Rybelsus, launched in 2022, has accelerated demand, contributing to the sector’s growth from $16 million in 2021 to nearly $100 million. Semaglutide was approved for medical use in the U.S. in 2017 and became the 19th most commonly prescribed medication in 2023, with over 25 million prescriptions. With significantly reduced prices, the drug could become a key component of India’s public health strategy, addressing both chronic diseases and the rising obesity epidemic.

India’s pharmaceutical industry, already the world’s largest supplier of generic medicines, is set to leverage semaglutide’s patent expiry to expand its global influence. The country’s ability to produce affordable generics has historically transformed global health, as seen with HIV antiretroviral drugs in the 2000s. During that period, Indian firms drastically lowered the cost of HIV medications, expanding treatment access across Africa and the developing world. Today, India supplies medicines to over 200 countries, meeting more than half of Africa’s generic drug demand, 40% of the U.S. market, and a quarter of the UK’s needs.

India’s generic drug exports currently total $30.46 billion, with the U.S. as its largest market. The export potential of Indian generic weight-loss drugs is substantial, with the U.S. market alone projected to scale to $10 billion within a few years as obesity rates rise.

This expansion could further solidify India’s role as the “pharmacy of the world,” while also pressuring global pharmaceutical giants to lower prices for branded semaglutide. However, the success of this export growth will depend on maintaining quality standards and navigating regulatory frameworks in target markets.

“Semaglutide, a GLP-1 receptor agonist, has become a critical tool in addressing obesity and diabetes in India.”

While the affordability of semaglutide generics represents a major breakthrough, it also raises critical regulatory and quality concerns. India’s drug regulator has issued an advisory cautioning pharmaceutical companies against directly promoting prescription weight-loss medicines to consumers, stressing the importance of medical supervision.

Advertising that promises dramatic results or downplays the need for diet and exercise could be deemed misleading. Doctors warn that rapid weight loss without adequate protein intake or physical activity can lead to muscle loss, while side effects such as nausea, vomiting, and gallstones remain risks. Experts like Muffazal Lakdawala, a Mumbai-based bariatric surgeon, emphasize that poor-quality generics could harm the drug’s reputation. Additionally, the increased affordability may lead to misuse, with patients seeking high doses from unqualified practitioners or online pharmacies.

Stricter regulations and oversight will be essential to balance accessibility with safety, ensuring the benefits of semaglutide are realized without compromising patient health.

Despite the promise of semaglutide generics, several challenges remain. First, the drug’s effectiveness relies on lifestyle modifications, yet many patients expect rapid weight loss without addressing diet or exercise. Mumbai-based diabetologist Rahul Baxi notes that patients often seek a “quick fix,” influenced by social media and celebrity endorsements.

This unrealistic expectation could result in poor adherence and suboptimal outcomes. Second, weight loss with GLP-1 drugs is often temporary, as appetite may rebound strongly once the medication is discontinued. Long-term use may be necessary, but the financial and logistical implications for patients and healthcare systems are still unclear.

Finally, the global expansion of India’s generics market will require navigating complex regulatory environments and ensuring equitable access in low- and middle-income countries. While the patent expiry represents a transformative moment, the true impact of semaglutide’s affordability will depend on how effectively India balances innovation, regulation, and public health priorities in the years ahead.